PF-Atlas › Clinical Trials › NCT04537533

Fisetin Senolytic in IPF

Fisetin · Senolytics · Phase 2

Registry ID
NCT04537533
Phase
Phase 2
Status
Recruiting
Drug / intervention
Fisetin
Mechanism
Senolytics
Sponsor
Multiple
Start
2021-04

About this trial

Fisetin is evaluated in NCT04537533, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Multiple, targeting senolytics. Current status: Recruiting.

View NCT04537533 on ClinicalTrials.gov →

Explore related

All Fisetin trialsSenolytics mechanismAll IPF trials

Related trials

Dasatinib + Quercetin — NCT04262635Navitoclax — NCT05166694
Medical disclaimer. This page summarizes public trial data for NCT04537533 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.